pI: 10.2513 |
Length (AA): 487 |
MW (Da): 54097 |
Paralog Number:
0
Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There are 3 models calculated for this protein. More info on
these models, including the
models themselves is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
1 | 479 | 5iso (A) | 13 | 445 | 24.00 | 0 | 1 | 0.992373 | 0.84 |
1 | 315 | 3ddq (C) | 1 | 292 | 40.00 | 0 | 1 | 0.893617 | 0.15 |
124 | 174 | 3es1 (A) | 93 | 143 | 31.00 | 0.95 | 0.49 | 0.497523 | -0.52 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Ortholog group members (OG5_143121)
Species | Accession | Gene Product |
---|---|---|
Arabidopsis thaliana | AT4G28980 | cyclin-dependent kinase F-1 |
Leishmania braziliensis | LbrM.28.0600 | mitogen-activated protein kinase, putative,map kinase, putative |
Leishmania donovani | LdBPK_280610.1 | Mitogen-activated protein kinase 8, putative |
Leishmania infantum | LinJ.28.0620 | mitogen-activated protein kinase, putative,map kinase, putative |
Leishmania major | LmjF.28.0580 | mitogen-activated protein kinase, putative,map kinase, putative |
Leishmania mexicana | LmxM.28.0580 | mitogen-activated protein kinase, putative,map kinase, putative |
Oryza sativa | 4340934 | Os06g0334400 |
Trypanosoma brucei gambiense | Tbg972.11.9330 | protein kinase, putative |
Trypanosoma brucei | Tb927.11.8170 | Mitogen-activated protein kinase 8, putative |
Trypanosoma congolense | TcIL3000.11.8720 | Mitogen-activated protein kinase 8, putative |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb11.01.0380 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (3 days) | alsford |
Tb11.01.0380 | Trypanosoma brucei | significant loss of fitness in bloodstream forms (6 days) | alsford |
Tb11.01.0380 | Trypanosoma brucei | no significant loss or gain of fitness in procyclic forms | alsford |
Tb11.01.0380 | Trypanosoma brucei | no significant loss or gain of fitness in differentiation of procyclic to bloodstream forms | alsford |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.
Species | Target | Length | Identity | Alignment span | Linked Drugs | Reference |
---|---|---|---|---|---|---|
Schizosaccharomyces pombe 972h- | Casein kinase II subunit alpha | 332 aa | 25.1% | 323 aa | Compounds | References |
Rattus norvegicus | Mitogen-activated protein kinase 1 | 358 aa | 27.2% | 324 aa | Compounds | References |
Rattus norvegicus | c-Jun N-terminal kinase 3 | 464 aa | 27.0% | 382 aa | Compounds | References |
Rattus norvegicus | MAP kinase p38 alpha | 360 aa | 30.9% | 356 aa | Compounds | References |
Plasmodium falciparum (isolate 3D7) | Cell division control protein 2 homolog | 288 aa | 30.6% | 310 aa | Compounds | References |
Homo sapiens | Cyclin-dependent kinase 1/cyclin B1 | 297 aa | 31.2% | 324 aa | Compounds | References |
Bos taurus | Glycogen synthase kinase-3 beta splice variant X1 | 419 aa | 27.7% | 336 aa | Compounds | References |
Oryctolagus cuniculus | Cyclin-dependent kinase 4 | 189 aa | 31.5% | 184 aa | Compounds | References |
Zea mays | Casein kinase II alpha | 332 aa | 26.6% | 323 aa | Compounds | References |
Rattus norvegicus | Mitogen-activated protein kinase 8 | 411 aa | 27.4% | 358 aa | Compounds | References |
Rattus norvegicus | Cell division protein kinase 5 | 292 aa | 29.9% | 324 aa | Compounds | References |
Patiria pectinifera | Cdc2 | 300 aa | 31.2% | 321 aa | Compounds | References |